Aurobindo Pharma Limited — Updates, 12-12-2025: General Updates
12-12-2025 | 05:12 pm
12-12-2025 | 05:12 pm
Aurobindo Pharma's subsidiary, Apitoria Pharma, received 3 procedural observations on a Form 483 following a US FDA inspection of its API manufacturing facility. The company clarifies this development has no impact on operations.
No comments yet. Be the first to comment!
